TABLE 2.
Kaplan-Meier analysis of outcomes for patients who were or were not taking MHSs and were being treated for prostate cancer with the use of definitive IMRT1
| MHS nonusers with events (total n = 1990), n (%) | % (95% CI) | MHS users with events (total n = 217), n (%) | % (95% CI) | Log-rank P | sHR (95% CI) | P | |
| 5-y FFBF all | 185 (9) | 89 (87, 91) | 17 (8) | 94 (89, 96) | 0.12 | 0.75 (0.45, 1.23 | 0.25 |
| Low risk | — | 96 (93, 97) | — | 99 (91, 100) | 0.37 | — | — |
| Intermediate risk | — | 87 (83, 90) | — | 88 (76, 94) | 0.68 | — | — |
| High risk | — | 78 (72, 84) | — | 88 (66, 96) | 0.27 | — | — |
| 5-y FFDM | 64 (3) | 96 (95, 97) | 5 (2) | 97 (93, 99) | 0.32 | 0.75 (0.30, 1.88 | 0.54 |
| 5-y CSS | 25 (1) | 99 (98, 100) | 1 (1) | 100 (96, 100) | 0.22 | 0.41 (0.05, 3.16 | 0.39 |
| 5-y OS | 171 (9) | 92 (91, 94) | 10 (5) | 97 (93, 99) | 0.012 | 0.61 (0.32, 1.16 | 0.133 |
1
Columns on the left side (number of events, their 95% CIs, and the log-rank P values) of the table (Kaplan Meier analysis) were unadjusted. Adjusted ratios are provided on the right side (sHRs and P values) of the table. CSS, cancer-specific survival; FFBF, freedom from biochemical failure; FFDM, freedom from distant metastasis; IMRT, intensity-modulated radiation therapy; MHS, men’s health supplement; OS, overall survival; sHR, subdistribution HR.
2
P < 0.05.